Adrenogenital syndrome
Also known as: Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Adrenogenital syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry E25.9: Adrenogenital syndrome is managed within Thyroid & Endocrine (aka Disorder).
- 3 Typical cash cost range: Primary evaluation for Adrenogenital syndrome incorporates autoimmune antibody titers [Adrenogenital syndrome E25.9] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Adrenogenital syndrome: Free Thyroxine (Free in Adrenogenital syndrome (E25.9: T4) & Free) (FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E25.9)) and Morning Serum Cortisol in Adrenogenital syndrome (E25.9: (8 AM)).
Ask our AI Specialists anything about Adrenogenital syndrome
What Is Adrenogenital syndrome?
Recognized across U.S. clinical coding as E25.9 (Thyroid & Endocrine), Adrenogenital syndrome (also termed Disorder or Syndrome) is evaluated via autoimmune antibody titers [Adrenogenital syndrome E25.9] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in thyroid & endocrine, Adrenogenital syndrome (E25.9) involves target-tissue metabolic rate in Adrenogenital syndrome (E25.9: perturbation). progression correlates with shifts in Free Thyroxine (Free in Adrenogenital syndrome (E25.9: T4) & Free) (FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E25.9)).
Common Symptoms & Clinical Signs
- • Presentation of Adrenogenital syndrome (E25.9): persistent fatigue, sluggish in Adrenogenital syndrome (E25.9: morning waking, or)
- • Secondary Adrenogenital syndrome clinical sign: dry skin, brittle in Adrenogenital syndrome (E25.9: nails, diffuse hair)
- • Symptom flares in Adrenogenital syndrome correlating with Free Thyroxine (Free in Adrenogenital syndrome (E25.9: T4) & Free) deviation outside FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E25.9)
- • Functional thyroid & endocrine impact requiring autoimmune antibody titers [Adrenogenital syndrome E25.9] evaluation (E25.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Adrenogenital syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E25.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Thyroid, Adrenal & Endocrine Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Free Thyroxine (Free in Adrenogenital syndrome (E25.9: T4) & Free) | FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E25.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Morning Serum Cortisol in Adrenogenital syndrome (E25.9: (8 AM)) | 10 – 18 mcg/dL (E25.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TPO & Thyroglobulin in Adrenogenital syndrome (E25.9: Antibodies) | Negative / < 9 IU/mL (E25.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Adrenogenital syndrome
Treatment selection for Adrenogenital syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Adrenogenital syndrome)
Human clinical trial evidence for Adrenogenital syndrome is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Adrenogenital syndrome Patient Community & “People Like Me” Threads
Filter Adrenogenital syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.